Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1889MR)

This product GTTS-WQ1889MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Cervical Cancer research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1889MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10457MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY2541546
GTTS-WQ10475MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY-2951742
GTTS-WQ7411MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GA201
GTTS-WQ10322MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LJM716
GTTS-WQ4301MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BIIB-054
GTTS-WQ6350MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ6504MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CX-072
GTTS-WQ2414MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 145
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW